AVIR [NASD]
Atea Pharmaceuticals, Inc.
Index- P/E49.91 EPS (ttm)0.11 Insider Own10.52% Shs Outstand83.26M Perf Week-1.90%
Market Cap489.23M Forward P/E- EPS next Y-2.60 Insider Trans0.00% Shs Float74.50M Perf Month-24.13%
Income15.50M PEG- EPS next Q-0.44 Inst Own70.10% Short Float3.09% Perf Quarter-22.05%
Sales225.00M P/S2.17 EPS this Y-235.80% Inst Trans4.55% Short Ratio5.16 Perf Half Y-21.19%
Book/sh7.93 P/B0.72 EPS next Y-39.80% ROA2.10% Target Price9.00 Perf Year-83.77%
Cash/sh7.96 P/C0.71 EPS next 5Y- ROE2.40% 52W Range5.31 - 46.91 Perf YTD-36.35%
Dividend- P/FCF- EPS past 5Y- ROI17.00% 52W High-87.87% Beta-
Dividend %- Quick Ratio27.50 Sales past 5Y- Gross Margin- 52W Low7.16% ATR0.40
Employees63 Current Ratio27.50 Sales Q/Q- Oper. Margin- RSI (14)28.12 Volatility7.20% 6.37%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin6.90% Rel Volume1.26 Prev Close5.60
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout0.00% Avg Volume446.68K Price5.69
Recom2.60 SMA20-15.38% SMA50-25.37% SMA200-21.08% Volume562,619 Change1.61%
Jan-06-22Downgrade Morgan Stanley Equal-Weight → Underweight $14 → $7
Nov-18-21Downgrade SVB Leerink Outperform → Mkt Perform
Oct-20-21Downgrade JP Morgan Overweight → Neutral $61 → $16
Oct-05-21Downgrade Morgan Stanley Overweight → Equal-Weight $55
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
Sep-27-22 09:53AM
Sep-26-22 09:33AM
07:00AM
Sep-13-22 09:56AM
07:00AM
07:00AM Loading…
Sep-07-22 07:00AM
Sep-06-22 08:18AM
Aug-09-22 06:00AM
Aug-08-22 04:30PM
04:05PM
Aug-01-22 07:00AM
Jul-13-22 12:00PM
Jul-11-22 07:00AM
Jul-07-22 08:45AM
Jul-02-22 10:23AM
09:37AM Loading…
Jun-12-22 09:37AM
Jun-01-22 07:00AM
May-25-22 06:20AM
May-11-22 10:28AM
May-10-22 07:00PM
06:30AM
May-03-22 04:05PM
Apr-01-22 05:13AM
Mar-30-22 12:48PM
Mar-28-22 07:00AM
Mar-21-22 10:04AM
Feb-28-22 10:00PM
07:19PM
06:40PM
04:05PM
07:00AM Loading…
Feb-22-22 07:00AM
Feb-16-22 02:19PM
01:57PM
Feb-14-22 09:31AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Feb-09-22 07:00AM
Feb-02-22 05:38PM
01:38PM
07:00AM
Jan-28-22 05:05AM
Jan-07-22 07:00AM
Jan-03-22 07:00AM
Dec-28-21 08:27AM
05:00AM
Dec-17-21 07:00AM
Dec-14-21 04:30PM
Dec-12-21 12:24PM
Dec-10-21 06:38PM
Dec-01-21 08:47AM
Nov-25-21 07:35AM
Nov-22-21 07:00AM
Nov-17-21 10:32AM
08:13AM
08:09AM
Nov-16-21 05:25PM
04:58PM
04:30PM
Nov-12-21 05:00AM
Nov-11-21 04:01PM
Nov-04-21 07:53AM
06:50AM
Nov-01-21 03:21PM
Oct-31-21 06:19AM
Oct-30-21 08:39AM
Oct-29-21 06:05AM
Oct-26-21 07:00AM
06:45AM
Oct-25-21 02:39PM
Oct-24-21 10:00AM
Oct-22-21 07:42PM
Oct-20-21 09:04PM
11:10AM
10:09AM
Oct-19-21 04:05PM
12:55PM
12:11PM
12:02PM
11:56AM
10:08AM
09:51AM
07:00AM
04:28AM
Oct-17-21 06:04AM
Oct-15-21 04:30PM
Oct-12-21 04:00PM
Oct-11-21 08:27AM
Oct-08-21 08:30AM
Oct-07-21 07:00AM
Oct-05-21 10:00AM
Oct-04-21 10:00AM
Oct-03-21 04:00PM
Oct-01-21 12:21PM
11:50AM
Sep-29-21 07:00AM
Sep-20-21 01:18PM
Sep-18-21 12:11PM
Sep-10-21 12:19PM
Sep-07-21 07:00AM
Aug-24-21 07:00AM
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murphy Polly A.DirectorDec 20Buy8.5712,000102,79623,295Dec 21 09:41 PM